Marginal Structural Cox Model Estimates for the Effect of Treatment Regimen on Postindex Virologic Failure (n = 532)
| Exposure . | Person-Years . | Number of Virologic Failure . | Crude HR (95% CI) . | IPTW×IPCW-Weighted Marginal Structural Model HR (95% CI) . |
|---|---|---|---|---|
| Exposure to PI/r with 2 NRTIs | 723.56 | 23 | 1 (reference) | 1 (reference) |
| Exposure to dolutegravir with 2 NRTIs | 291.54 | 5 | 0.54 (0.23–1.24) | 0.57 (0.21–1.52) |
| Exposure . | Person-Years . | Number of Virologic Failure . | Crude HR (95% CI) . | IPTW×IPCW-Weighted Marginal Structural Model HR (95% CI) . |
|---|---|---|---|---|
| Exposure to PI/r with 2 NRTIs | 723.56 | 23 | 1 (reference) | 1 (reference) |
| Exposure to dolutegravir with 2 NRTIs | 291.54 | 5 | 0.54 (0.23–1.24) | 0.57 (0.21–1.52) |
Abbreviations: CI, confidence interval; HR, hazard ratio; IPCW, inverse probability of censoring weights; IPTW, inverse probability of treatment weights; NRTIs, nucleoside reverse-transcriptase inhibitors; PI/r, protease inhibitor/ritonavir.
Marginal Structural Cox Model Estimates for the Effect of Treatment Regimen on Postindex Virologic Failure (n = 532)
| Exposure . | Person-Years . | Number of Virologic Failure . | Crude HR (95% CI) . | IPTW×IPCW-Weighted Marginal Structural Model HR (95% CI) . |
|---|---|---|---|---|
| Exposure to PI/r with 2 NRTIs | 723.56 | 23 | 1 (reference) | 1 (reference) |
| Exposure to dolutegravir with 2 NRTIs | 291.54 | 5 | 0.54 (0.23–1.24) | 0.57 (0.21–1.52) |
| Exposure . | Person-Years . | Number of Virologic Failure . | Crude HR (95% CI) . | IPTW×IPCW-Weighted Marginal Structural Model HR (95% CI) . |
|---|---|---|---|---|
| Exposure to PI/r with 2 NRTIs | 723.56 | 23 | 1 (reference) | 1 (reference) |
| Exposure to dolutegravir with 2 NRTIs | 291.54 | 5 | 0.54 (0.23–1.24) | 0.57 (0.21–1.52) |
Abbreviations: CI, confidence interval; HR, hazard ratio; IPCW, inverse probability of censoring weights; IPTW, inverse probability of treatment weights; NRTIs, nucleoside reverse-transcriptase inhibitors; PI/r, protease inhibitor/ritonavir.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
